| Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma PA Konstantinopoulos, S Waggoner, GA Vidal, M Mita, JW Moroney, ... JAMA oncology 5 (8), 1141-1149, 2019 | 468 | 2019 |
| The Fanconi anemia pathway in cancer J Niraj, A Färkkilä, AD D'Andrea Annual review of cancer biology 3 (1), 457-478, 2019 | 375 | 2019 |
| Vascular endothelial growth factor-C accelerates diabetic wound healing A Saaristo, T Tammela, A Fārkkilā, M Kärkkäinen, E Suominen, ... The American journal of pathology 169 (3), 1080-1087, 2006 | 305 | 2006 |
| A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors J Zhou, C Gelot, C Pantelidou, A Li, H Yücel, RE Davis, A Färkkilä, ... Nature cancer 2 (6), 598-610, 2021 | 273 | 2021 |
| Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer A Färkkilä, DC Gulhan, J Casado, CA Jacobson, H Nguyen, ... Nature communications 11 (1), 1459, 2020 | 235 | 2020 |
| Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial PA Konstantinopoulos, SC Cheng, AEW Hendrickson, RT Penson, ... The Lancet Oncology 21 (7), 957-968, 2020 | 189 | 2020 |
| The CHK1 inhibitor prexasertib exhibits monotherapy activity in high-grade serous ovarian cancer models and sensitizes to PARP inhibition K Parmar, BS Kochupurakkal, JB Lazaro, ZC Wang, S Palakurthi, ... Clinical Cancer Research 25 (20), 6127-6140, 2019 | 129 | 2019 |
| Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation J Duraiswamy, R Turrini, A Minasyan, D Barras, I Crespo, AJ Grimm, ... Cancer cell 39 (12), 1623-1642. e20, 2021 | 117 | 2021 |
| A functional homologous recombination assay predicts primary chemotherapy response and long-term survival in ovarian cancer patients M Tumiati, S Hietanen, J Hynninen, E Pietilä, A Färkkilä, K Kaipio, ... Clinical Cancer Research 24 (18), 4482-4493, 2018 | 110 | 2018 |
| Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary A Färkkilä, UM Haltia, J Tapper, MK McConechy, DG Huntsman, ... Annals of Medicine 49 (5), 435-447, 2017 | 104 | 2017 |
| Genetically defined syngeneic mouse models of ovarian cancer as tools for the discovery of combination immunotherapy S Iyer, S Zhang, S Yucel, H Horn, SG Smith, F Reinhardt, E Hoefsmit, ... Cancer Discovery 11 (2), 384-407, 2021 | 92 | 2021 |
| Clinical characteristics and survival of patients with an adult-type ovarian granulosa cell tumor: a 56-year single-center experience S Bryk, A Färkkilä, R Bützow, A Leminen, M Heikinheimo, M Anttonen, ... International Journal of Gynecologic Cancer 25 (1), 2015 | 77 | 2015 |
| Anti-Müllerian hormone inhibits growth of AMH type II receptor-positive human ovarian granulosa cell tumor cells by activating apoptosis M Anttonen, A Färkkilä, H Tauriala, M Kauppinen, DT MacLaughlin, ... Laboratory investigation 91 (11), 1605-1614, 2011 | 77 | 2011 |
| Molecularly defined adult granulosa cell tumor of the ovary: the clinical phenotype MK McConechy, A Färkkilä, HM Horlings, A Talhouk, L Unkila-Kallio, ... Journal of the National Cancer Institute 108 (11), djw134, 2016 | 72 | 2016 |
| FOXL2, GATA4, and SMAD3 co-operatively modulate gene expression, cell viability and apoptosis in ovarian granulosa cell tumor cells M Anttonen, M Pihlajoki, N Andersson, A Georges, D L'hôte, S Vattulainen, ... PLoS One 9 (1), e85545, 2014 | 69 | 2014 |
| TERT promoter mutation in adult granulosa cell tumor of the ovary JA Pilsworth, DR Cochrane, Z Xia, G Aubert, AEM Färkkilä, HM Horlings, ... Modern Pathology 31 (7), 1107-1115, 2018 | 66 | 2018 |
| The clinical utility of serum anti‐M üllerian hormone in the follow‐up of ovarian adult‐type granulosa cell tumors—A comparative study with inhibin B A Färkkilä, S Koskela, S Bryk, H Alfthan, R Bützow, A Leminen, U Puistola, ... International Journal of Cancer 137 (7), 1661-1671, 2015 | 66 | 2015 |
| Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer IM Launonen, N Lyytikäinen, J Casado, EA Anttila, A Szabó, UM Haltia, ... Nature communications 13 (1), 835, 2022 | 62 | 2022 |
| Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors A Färkkilä, M Anttonen, J Pociuviene, A Leminen, R Butzow, ... European journal of endocrinology 164 (1), 115-122, 2011 | 61 | 2011 |
| Characteristics and outcome of recurrence in molecularly defined adult-type ovarian granulosa cell tumors S Bryk, A Färkkilä, R Bützow, A Leminen, J Tapper, M Heikinheimo, ... Gynecologic Oncology 143 (3), 571-577, 2016 | 49 | 2016 |
